Managing Insomnia Using Lucid Dreaming Training: A Pilot Study.
Jason G Ellis, Joseph De Koninck, Celyne H Bastien
Behavioral sleep medicine January 1, 2021 DOI: 10.1080/15402002.2020.1739688 via PubMed
Summary
AI-generated from the abstractLucid Dreaming Training for insomnia (LDT-I) may help reduce insomnia severity, anxiety, and depression. In an open-label trial of 48 adults with Insomnia Disorder, participants completed four training modules over two weeks. One month later, insomnia severity, anxious symptomology, and depressive symptomology all showed significant reductions. The effect on insomnia severity was large. The authors caution that these preliminary results require further testing before LDT-I can be established as a non-pharmacological treatment for insomnia.
Study at a glance
| Characteristics | Open-label trial Pilot study Peer reviewed |
|---|---|
| Sample size | 48 |
| Population | Adults with Insomnia Disorder |
| Intervention | Lucid Dreaming Training for insomnia |
| Duration | Two-week intervention, one-month follow-up |
| Citations | 27 |
| Key finding | Lucid Dreaming Training for insomnia significantly reduced insomnia severity, anxiety, and depression in adults with Insomnia Disorder. |
Abstract
Objectives/Background: Despite Cognitive Behavioral Therapy for Insomnia (CBT-I) being considered the first-line treatment for insomnia, it is not without its challenges. As such it is worthwhile to consider, and test, alternative or adjuvant management options. Methods/Participants: The aim of the present study was to examine whether Lucid Dreaming Training for insomnia (LDT-I) impacted on insomnia, depressive and anxious symptomology in an open label trial of 48 adults with Insomnia Disorder. Participants completed the Insomnia Severity Index, General Anxiety Disorder-7 and Patient Health Questionnaire at baseline then one month following LDT-I. Training consisted of four modules delivered over a period of two consecutive weeks. Results: The results suggest, albeit preliminarily, that LDT-I may have a place within the non-pharmacological management of insomnia, as there were significant reductions in insomnia severity (t(46) = 8.16,p <.001), anxious symptomology (t(46) = 4.75,p <.001) and depressive symptomology (t(46) = 5.87,p <.001). Further, the effect size in terms of pre-post reductions on ISI scores was large (dz 1.17). Conclusions: Whilst the results are promising, further testing of LDT-I is needed to inform its place amongst the non-pharmacological treatments for insomnia.